We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cell Therapeutics Spin-off to Use Genetic Technology to Develop Biopharmaceuticals
News

Cell Therapeutics Spin-off to Use Genetic Technology to Develop Biopharmaceuticals

Cell Therapeutics Spin-off to Use Genetic Technology to Develop Biopharmaceuticals
News

Cell Therapeutics Spin-off to Use Genetic Technology to Develop Biopharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cell Therapeutics Spin-off to Use Genetic Technology to Develop Biopharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cell Therapeutics, Inc. (CTI) has announced that it plans to form a new spin-off company, Aequus BioPharma, Inc. to develop a Genetic Polymer™ technology that was created at CTI to speed the manufacture, development and commercialization of biopharmaceuticals including follow-on biologics or so-called biosimilars.

"Pharmaceutical companies and regulatory agencies need to bring the cutting-edge benefits of biotech drugs to patients as quickly, safely and at the lowest cost possible," said CTI's President and CEO, James A. Bianco, M.D.

"A key pitfall of protein therapeutics has been the relatively short plasma life of these types of drugs, which leads to the need for frequent injections and higher associated costs for therapies.

Aequus BioPharma will utilize the Genetic Polymer technology, discovered at CTI, which we expect to extend the plasma half-life of therapeutic proteins and provide a potentially less expensive, streamlined development pathway for next generation biologics like Neulasta® or Aranesp®."

"In addition to its application in producing lower cost follow-on biologics, we believe this recombinant technology might be utilized to develop novel biologics and also deliver small inhibitors of RNA (siRNA), to their cellular targets in a wide array of malignant, inflammatory, or infectious diseases.” noted Bianco.

“We have begun recruiting a scientific and management team, including former members of the Immunex-Enbrel management team, that will have the requisite experience in protein therapeutic development and will take the lead on this new venture to speed follow-on biologics to market and patients," Bianco continued.

The Genetic Polymer technology can be used with multiple molecules, which may eliminate the need to develop individualized technology for extending the plasma half-life of each biopharmaceutical.

The Genetic Polymer technology is a recombinant DNA process that ligates a secretion sequence with a biologically active protein sequence and a poly-amino acid sequence resulting in a patentable gene.

CTI believes that expression in traditional mammalian cell systems will allow for the production of a biologic protein with prolonged plasma half-life, but without the requirement for further chemical modifications subsequent to protein expression, thus potentially speeding the manufacturing process and lowering the cost of goods.

The Company believes this proprietary recombinant Genetic Polymer technology creates compositions of matter and will allow for the manufacture and sale of protein biologics like G-CSF or EPO without infringing on the patents of other companies with competing technologies as well as allowing for more convenient dosing.

CTI believes it has demonstrated a preliminary proof of principle of the Genetic Polymer technology and Aequus BioPharma is anticipated to generate additional experimental data to validate the technology. The first biologics the Company plans to move into preclinical study include a long-acting G-CSF and EPO biosimilar.

Advertisement